CClinicalTrials.gg
Not yet recruitingNCT07686302Updated Jul 7, 2026

Feasibility of Noninvasive Trigeminal Nerve Stimulation During Exercise

An interventional study of Active Stimulation and Sham Stimulation in COPD, sponsored by Johns Hopkins University. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to examine 1) effects of cutaneous electrical trigeminal nerve stimulation (eTNS) on respiratory control in healthy volunteers and 2) explore the potential of this approach to mitigate dyspnea in patients with chronic obstructive lung disease (COPD).

02

Conditions studied

  • COPD

Keywords

  • dyspnea
  • Control of breathing
  • neural stimulation
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Arm1 - Healthy Volunteers

Inclusion Criteria:

  • Adults aged 18-50 years
  • BMI 18-30 kg/m²
  • Ability to provide informed consent and complete study procedures in English

Exclusion Criteria:

  • Current daytime respiratory impairment such as uncontrolled asthma, uncontrolled COPD, pneumonia, or interstitial lung disease
  • Use of supplemental oxygen
  • Pregnancy or breastfeeding
  • Current use of acetazolamide, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, or daily opioids
  • History of claustrophobia or panic disorder
  • Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or electrical stimulation
  • Implanted cardiac or neuroelectric device (e.g., pacemaker, implantable cardioverter-defibrillator (ICD), deep brain stimulator, vagus nerve stimulator, implanted drug pump)
  • Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites
  • Resting heart rate \<60 Beats Per Minute
  • History of seizure disorder or epilepsy

Arm 2 -COPD

Inclusion Criteria:

  • Adults aged 40-75 years
  • Confirmed diagnosis of COPD by spirometry (post-bronchodilator Forced Expiratory Volume (FEV1) /Forced Vital Capacity (FVC) \<0.70) or provider documentation in medical records
  • Modified Medical Research Council (mMRC) dyspnea grade ≥2
  • Stable COPD (no exacerbation requiring hospitalization, systemic corticosteroids, or antibiotic therapy within the preceding 6 weeks)
  • On stable COPD therapy for at least 4 weeks prior to enrollment
  • Ability to provide informed consent and complete questionnaires in English
  • Resting Peripheral Capillary Oxygen Saturation (SpO₂) ≥88% on room air or prescribed supplemental oxygen

Exclusion Criteria:

  • Unstable cardiovascular disease (e.g., unstable angina, decompensated heart failure, recent MI within 6 months, uncontrolled arrhythmia) or peripheral vascular disease
  • Patients with cardiovascular disease, including chest pain, heart failure, and aortic stenosis
  • Resting heart rate \<60 BPM
  • Implanted cardiac or neuroelectric device (e.g., pacemaker, ICD, deep brain stimulator, vagus nerve stimulator, implanted drug pump)
  • Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or stimulation
  • Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites
  • Active trigeminal neuralgia or other cranial neuropathy
  • History of seizure disorder or epilepsy
  • Severe or uncontrolled psychiatric disorder (e.g., psychosis, severe untreated anxiety or panic disorder) that would impair the ability to participate
  • Pregnancy or breastfeeding
  • COPD exacerbation requiring hospitalization, systemic corticosteroids, or antibiotics within the preceding 3 months
  • Musculoskeletal pain, injury, or any other condition that precludes the use of a stationary bike for Cardiopulmonary Exercise Test (CPET)
  • Any condition that, in the opinion of the investigator, would compromise participant safety or data integrity
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Healthy Volunteers

    Procedure: Active Stimulation · Procedure: Sham Stimulation

  • Experimental
    Participants With COPD

    Procedure: Active Stimulation · Procedure: Sham Stimulation · Procedure: Fan therapy

Interventions

  • ProcedureActive Stimulation

    Active Non-Invasive Trigeminal Nerve Stimulation

  • ProcedureSham Stimulation

    Sham Stimulation

  • ProcedureFan therapy

    Handheld fan

05

What researchers measure

Primary outcomes

  1. Proportion of participants with a >4 bpm decrease in heart rate

    Trigeminal autonomic engagement. Proportion of participants with a \>4 bpm decrease in heart rate during active eTNS compared to sham stimulation.

    Time frame: 1 day

  2. Proportion of enrolled participants who complete all randomized stimulation conditions

    Protocol completion rate measured by proportion of enrolled participants who complete all randomized stimulation conditions.

    Time frame: 1 day

Secondary outcomes

  1. Minute Ventilation

    Minute Ventilation

    Time frame: 1 day

  2. Dyspnea severity as assessed by the Borg CR10 scale

    Borg CR10 score before and during stimulation. Scale range 0-10 higher score worse severity

    Time frame: 1 day

Other outcomes

  1. Change in heart rate

    changes in heart rate in response to stimulation

    Time frame: 1 day

  2. Change in heart rate variability

    changes in heart rate variability in response to stimulation

    Time frame: 1 day

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07686302
Lead sponsor
Johns Hopkins University
Collaborators
Center for Bioengineering Innovation and Design
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Luu Pham, MD
Contact
luu.pham@jhmi.edu
410-550-2118
Luu Pham, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion